TriSalus Life Sciences (TLSI) Change in Receivables (2022 - 2026)

TriSalus Life Sciences has reported Change in Receivables for 5 years, with the latest figure at -$1.3 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Receivables fell 452.73% year-over-year to -$1.3 million; the trailing twelve-month figure through Mar 2026 stood at -$23000.0 (down 101.69% YoY), and the FY2025 full-year result was $1.6 million, down 4.94% from the prior year.
• Change in Receivables for Q1 2026 stood at -$1.3 million, down from $1.6 million in the prior quarter.
• The five-year high for Change in Receivables was $1.6 million in Q4 2025, with the low at -$1.3 million in Q1 2026.
• Historically, Change in Receivables has averaged $236071.4 across 5 years, with a median of $363500.0 in 2024.
• Annual changes were most pronounced in 2024 — Change in Receivables surged 1965.71% — and 2026, when it slumped 452.73%.
• TriSalus Life Sciences' Change in Receivables stood at -$736000.0 in 2022, then soared by 168.21% to $502000.0 in 2023, then declined by 28.09% to $361000.0 in 2024, then jumped by 340.72% to $1.6 million in 2025, then tumbled by 181.14% to -$1.3 million in 2026.
• The last three Change in Receivables figures came in at -$1.3 million (Q1 2026), $1.6 million (Q4 2025), and -$497000.0 (Q3 2025), per Business Quant data.